B
Blue Oak Pharmaceuticals
Next generation drugs for brain disorders
About Blue Oak Pharmaceuticals
Blue Oak Pharmaceuticals specializes in discovering the next generation of drugs for brain disorders. The company integrates in vivo phenotypic assays, a unique chemistry platform, and high-content data analysis to identify new treatments for conditions such as bipolar disorder, depression, and schizophrenia. Blue Oak Pharmaceuticals operates in the biotechnology sector, targeting pharmaceutical companies and healthcare providers as its primary clients. The business model revolves around leveraging proprietary technology and a global network of research partners to accelerate drug discovery and development. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of developed drugs. The company aims to transform the CNS (Central Nervous System) drug discovery paradigm by focusing on systems-level neurobiology measures and translational biomarkers, ensuring rapid clinical confirmation.
Source: Dealroom company dataNews
Open roles
Blue Oak Pharmaceuticals in the Waltham ecosystem
The Blue Oak Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A1 investor entered at this stage
Viva Ventures Biotech Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Blue Oak Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Blue Oak Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
